Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome (vEDS) Confirmed With COL3A1 Mutations, Followed by an Open Label Extension (OLE)

NCT05463679 is registered in ClinicalTrials.gov with Aytu BioPharma, Inc. as lead sponsor.

NCT NCT05463679
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05463679 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome (vEDS) Confirmed With COL3A1 Mutations, Followed by an Open Label Extension (OLE)
Lead sponsor
Aytu BioPharma, Inc.
Phase
Phase 3
Overall status
Suspended
Start date
January 31, 2025
Completion date
March 31, 2027
Enrollment
260 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

vascular ehlers-danlos syndrome